Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

Nat Commun. 2022 Oct 7;13(1):5907. doi: 10.1038/s41467-022-33599-w.


The therapeutic effectiveness of oncolytic viruses (OVs) delivered intravenously is limited by the development of neutralizing antibody responses against the virus. To circumvent this limitation and to enable repeated systemic administration of OVs, here we develop Synthetic RNA viruses consisting of a viral RNA genome (vRNA) formulated within lipid nanoparticles. For two Synthetic RNA virus drug candidates, Seneca Valley virus (SVV) and Coxsackievirus A21, we demonstrate vRNA delivery and replication, virus assembly, spread and lysis of tumor cells leading to potent anti-tumor efficacy, even in the presence of OV neutralizing antibodies in the bloodstream. Synthetic-SVV replication in tumors promotes immune cell infiltration, remodeling of the tumor microenvironment, and enhances the activity of anti-PD-1 checkpoint inhibitor. In mouse and non-human primates, Synthetic-SVV is well tolerated reaching exposure well above the requirement for anti-tumor activity. Altogether, the Synthetic RNA virus platform provides an approach that enables repeat intravenous administration of viral immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing
  • Immunotherapy
  • Liposomes
  • Mice
  • Nanoparticles
  • Neoplasms* / therapy
  • Oncolytic Virotherapy*
  • Oncolytic Viruses* / genetics
  • Picornaviridae*
  • RNA, Viral / genetics
  • Tumor Microenvironment


  • Antibodies, Neutralizing
  • Lipid Nanoparticles
  • Liposomes
  • RNA, Viral

Supplementary concepts

  • Senecavirus A